Kiniksa Pharmaceuticals International, plc
76.73USD
-4.0600 (-5.03%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on KNSA.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Price
Reading the stored fundamentals…
Dated 52-week rows are the highest and lowest CLOSE and the day each happened, which sits a little inside the intraday range a vendor quotes. Quotes are refreshed once a night — during a session the price above is the previous close.
Is the price low against peers, cash flow and analyst targets?
1 of 6 checks could not be assessed (no PEG ratio is stored).
Do analysts expect earnings and revenue to keep growing?
1 of 6 checks could not be assessed (there is no analyst coverage stored).
Has the business grown and earned good returns on its filed numbers?
1 of 6 checks could not be assessed (the figures they need are not meaningful here).
Can the balance sheet carry its debt?
1 of 6 checks could not be assessed (the stored data lacks the figures they need).
Is the dividend decent, covered and steady?
No dividend appears in the stored data, so this axis is left off the shape rather than drawn as zero.
An axis marked n/a has no vertex: it is left out of the shape rather than drawn as zero.
Each axis asks six plain questions of the stored data. A check that passes counts one. A check the stored data cannot answer is left out of the count, never counted as a fail, and an axis needs four answerable checks to show a result. Axes are never added together: there is no overall score. The thresholds are conventional rules of thumb and are blunt across sectors, so each check is listed with its rule and the figure it used.
P/E below peers
Trailing P/E is positive and below the median of its peers: the companies in its industry if there are at least 5, else its sector if at least 10, else the whole market if at least 30, always in the same currency.
P/E 77.5 against a peer median of 31.9 (86 USD companies in the Healthcare sector).
Did not pass
PEG ratio
The PEG ratio is positive and at most 1.5.
No PEG ratio is stored; it needs analyst growth estimates.
Not assessed
EV/EBITDA below peers
EV/EBITDA is positive and below the peer median, with peers chosen as for P/E. Not applied to financial companies.
EV/EBITDA 53.6 against a peer median of 8.9 (8 USD companies in Drug Manufacturers - Specialty & Generic).
Did not pass
Price/book below peers
Price to book is positive and below the peer median, with peers chosen as for P/E.
Price/book 9.15 against a peer median of 10.66 (9 USD companies in Drug Manufacturers - Specialty & Generic).
Statements: SEC filings, newest period 03/2026.
Peers: P/E against 86 USD companies in the Healthcare sector; EV/EBITDA against 8 USD companies in Drug Manufacturers - Specialty & Generic; price/book against 9 USD companies in Drug Manufacturers - Specialty & Generic.
Rules of thumb applied to stored filings and quote data. Statements are as of the newest period shown above; multiples, analyst targets, estimates and yield come from a best-effort refresh and can lag by days. A count of plain checks, not a rating, a valuation or investment advice. Terms
Passed
Free cash flow yield
Free cash flow is at least 4.5% of market cap, the risk-free rate used across this site. Not applied to financial companies.
Free cash flow yield 2.8% against a 4.5% risk-free rate.
Did not pass
Analyst target above price
The mean analyst target is at least 15% above the last close, from at least 3 analysts. A published consensus, not a fair value.
Mean analyst target above the last close by 27.7% (8 analysts).
Passed
Earnings growth, next year
Consensus EPS for next fiscal year is at least 10% above this year's consensus, from at least 3 analysts.
Next year's EPS: consensus up 39.0% (4 analysts).
Passed
Earnings growth, this year
Consensus EPS for this fiscal year is at least 10% above last year's figure on the same street basis, from at least 3 analysts.
This year's EPS: consensus up 56.3% (4 analysts).
Passed
Revenue growth, next year
Consensus revenue for next fiscal year is at least 5% above this year's consensus, from at least 3 analysts.
Next year's revenue: consensus up 22.8% (8 analysts).
Passed
Revenue growth, this year
Consensus revenue for this fiscal year is at least 5% above last year's reported revenue, from at least 3 analysts.
This year's revenue: consensus up 47.0% (8 analysts).
Passed
Estimates rising
More analysts raised than cut this year's EPS estimate over the last 90 days, with at least 2 revisions in all.
No analyst estimates are stored for this security.
Not assessed
Revenue growth, latest quarter
Revenue in the latest quarter is at least 8% above the same quarter a year earlier.
Latest-quarter revenue up 55.5% on a year earlier.
Passed
Earnings growth, multi-year
Net income grew at least 5% a year over up to 5 fiscal years (at least 3 annual figures, positive at both ends).
Net income was not positive in FY2020, so there is no base to grow from.
Not assessed
Earnings growth, last year
Net income over the latest twelve months is above the twelve months before it, and positive.
Net income turned positive after a loss (twelve months to 03/2026).
Passed
Revenue growth, multi-year
Revenue grew at least 3% a year over up to 5 fiscal years (at least 3 annual figures).
Revenue grew 104.8% a year, FY2021 to FY2025.
Passed
Return on equity
Return on equity is at least 15%: twelve-month net income over average equity. Not meaningful when equity is negative.
Return on equity 13.7%: twelve-month net income over the average equity.
Did not pass
Return on assets
Return on assets is at least 5%: twelve-month net income over average assets. Not applied to financial companies.
Return on assets 10.3%: twelve-month net income over the average assets.
Passed
Cash earnings
Operating cash flow over the latest twelve months is positive and at least net income. Not applied to financial companies.
Operating cash flow was at or above net income over the last twelve months.
Passed
Current ratio
Current assets are at least 1.0x current liabilities. Not applied to financial companies.
Current ratio 3.8x.
Passed
Short-term assets cover long-term liabilities
Current assets are at least the liabilities that fall due after a year (total liabilities less current liabilities). Not applied to financial companies.
Current assets are 9.4x the liabilities due after a year.
Passed
Debt to equity
Total debt is at most 100% of equity; no debt passes, negative equity with debt does not. Not applied to financial companies.
Total debt is 1% of equity.
Passed
Net debt to EBITDA
Net debt (total debt less cash) is at most 3.0x EBITDA; a net cash position passes. Not applied to financial companies.
Net cash: cash exceeds total debt.
Passed
Interest cover
Operating income covers interest expense at least 3.0x; no debt passes. Not applied to financial companies.
No interest expense is stored.
Not assessed
Cash flow to debt
Operating cash flow is at least 20% of total debt; no debt passes. Not applied to financial companies.
Operating cash flow is 1864.2% of total debt.
Passed
Dividend yield
The dividend yield is at least 2%.
No dividend appears in the stored data.
Not assessed
Payout ratio
Dividends paid are at most 75% of net income. Not applied to real estate companies, whose net income is after depreciation.
No dividend appears in the stored data.
Not assessed
Free cash flow cover
Free cash flow covers the dividends paid at least 1.0x. Not applied to financial companies.
No dividend appears in the stored data.
Not assessed
Paid every year
A dividend was paid in every one of the last 4 to 8 fiscal years stored (consecutive years, all present). A year missing from the filings data is not read as no dividend, so a gap makes this not assessed.
No dividend appears in the stored data.
Not assessed
No cuts
Total dividends paid never fell by more than 20% from one fiscal year to the next in that window.
No dividend appears in the stored data.
Not assessed
Growing dividend
Total dividends paid grew at least 3% a year across that window. The total, not per share: no per-share dividend history is stored.
No dividend appears in the stored data.
Not assessed